Today before the opening bell, International Stem Cell Corp. reported that Co-Chairman of the Board and Chief Executive Officer Andrey Semechkin PhD has published an open letter to shareholders.
Dr. Semechkin’s letter provides an update on the stem cell company’s research and development accomplishments, future expectations and anticipated milestones, along with a discussion of ISCO’s expanded intellectual property portfolio and a summary of the company’s commercial and financial performance for the first nine months of 2013.
The full text of the letter can be found at http://www.internationalstemcell.com/2014_Shareholder_Letter
International Stem Cell Corp. specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
For more information visit www.internationalstemcell.com
Let us hear your thoughts: International Stem Cell Corp. Message Board